PeruLegal Representation for Pharmaceuticals in Peru
Entering the Peru pharmaceuticals market requires a locally accredited legal representative before DIGEMID will accept any product registration or import authorization. Taevas Global provides end-to-end legal representation so pharmaceuticals manufacturer
Six Pillars of Peru Pharmaceuticals Intelligence
Our legal representation service is built on six interconnected pillars that cover every dimension a pharmaceuticals company needs to establish, operate, and grow within Peru's regulated market.
DIGEMID Registration Management
We act as your officially designated legal representative before DIGEMID, the sole national authority for pharmaceutical product authorization in Peru. Our team prepares, submits, and tracks all Registro Sanitario dossiers in accordance with current DIGEMID technical requirements and the Pan American Network for Drug Regulatory Harmonization standards. Every submission is reviewed for completeness before filing to minimize objection cycles.
From Brief to Board-Ready Intelligence
Our four-stage engagement model takes you from initial scoping through to a fully established legal representation structure, with clear milestones and deliverables at every stage.
Regulatory Scoping and Gap Analysis
We begin with a structured intake session to understand your product portfolio, existing regulatory dossiers, and target launch timeline in Peru. Our regulatory specialists then conduct a gap analysis comparing your current documentation against DIGEMID's current technical requirements for Registro Sanitario. The output is a prioritized action plan identifying every document, certificate, and translation needed before submission.
The gap analysis covers product classification under DIGEMID categories, GMP certificate validity and apostille requirements, labeling compliance with Peruvian Spanish requirements, and any controlled substance scheduling implications. You receive a written gap report with document checklist, estimated timelines per product, and a fee schedule for the full engagement. This stage requires no commitment beyond the initial scoping fee and gives you a clear picture of the full investment before proceeding.
Peru Pharmaceuticals Market at a Glance
Growing Middle Class Driving Demand
Peru's expanding middle class and increased public health spending under MINSA and EsSalud are driving sustained demand for branded and generic pharmaceuticals across therapeutic categories. The government's Universal Health Coverage agenda has increased the number of Peruvians with formal health insurance, expanding the addressable patient population for prescription medicines. This structural demand growth makes Peru one of the most attractive pharmaceutical markets in the Andean region.
DIGEMID Modernization Creating New Pathways
DIGEMID has progressively modernized its registration processes, introducing an expedited pathway for products already authorized by reference regulatory agencies including the US FDA, EMA, Health Canada, TGA, and Brazil's ANVISA. This pathway can reduce registration timelines from over 180 days to as few as 30 days for qualifying products, significantly lowering the barrier to entry for internationally approved pharmaceuticals. Companies with multi-market authorization portfolios are well positioned to leverage this accelerated route.
Public Procurement Represents Significant Revenue
EsSalud and MINSA together represent a substantial share of pharmaceutical purchasing in Peru, with centralized tender processes conducted through the national procurement platform SEACE. Inclusion on the Petitorio Nacional Unico de Medicamentos Esenciales (PNUME), the essential medicines list, is a prerequisite for participation in most public tenders and can significantly accelerate volume growth. Foreign manufacturers with a local legal representative are eligible to participate directly or through registered distributors.
Generics and Biosimilars Gaining Market Share
Peru's government has actively promoted generic medicine use through prescription-by-international-nonproprietary-name policies and public awareness campaigns, increasing generic penetration across the retail and institutional channels. The biosimilars segment is emerging as DIGEMID develops its regulatory framework for biological products, creating an early-mover opportunity for manufacturers with approved biosimilar portfolios in reference markets. Companies that establish legal representation and registration infrastructure now will be positioned to capture share as this segment matures.
Everything in Your Engagement
Every Taevas Global legal representation engagement for Peru pharmaceuticals includes these eight core deliverables, ensuring you have complete documentation, regulatory standing, and strategic clarity from day one.
Regulatory Gap Analysis Report
A written assessment of your product portfolio against current DIGEMID requirements, identifying every document, certificate, and translation needed before submission with estimated timelines and costs per product.
Poder Notarial and Legal Representative Designation
Preparation and execution of the notarized power of attorney and all DIGEMID filings required to officially designate Taevas Global as your legal representative in Peru, recorded in DIGEMID's system within five business days.
Registro Sanitario Dossier Preparation
Complete compilation, translation, and pre-submission review of your pharmaceutical dossier for each product, formatted to DIGEMID's current technical requirements and submitted under the optimal registration pathway.
DIGEMID Submission and Query Management
Official submission of all dossiers to DIGEMID and management of all authority correspondence, technical queries, and observations throughout the evaluation period, with bi-weekly status reports to your team.
Import Authorization Management
Preparation and submission of DIGEMID import authorizations for each product shipment, coordinated with SUNAT customs documentation to ensure uninterrupted supply chain operations from first commercial import.
Legal Entity and Distribution Agreement Advisory
Guidance on optimal legal structure for Peru market operations and review or drafting of distribution, agency, and supply agreements under Peruvian civil and commercial law to protect your interests and IP.
Pharmacovigilance Compliance Setup
Establishment of your pharmacovigilance reporting system in compliance with DIGEMID's post-market surveillance requirements, including adverse event reporting procedures, annual safety report templates, and signal management protocols.
Ongoing Representation Retainer and Compliance Calendar
A dedicated Lima-based account manager providing continuous legal representation, a 12-month compliance calendar with all renewal and reporting deadlines, and quarterly regulatory intelligence updates on DIGEMID policy developments.
Built for These Situations
Pharmaceuticals Manufacturer Entering Peru for the First Time
You have products approved in the US, EU, or other reference markets and want to access Peru's growing pharmaceuticals market, but you have no local legal entity, no DIGEMID relationship, and no in-country regulatory staff. DIGEMID requires a locally registered legal representative before it will accept any product registration application, making this the mandatory first step before any other market entry activity. Taevas Global provides the complete legal representation infrastructure so you can begin the registration process immediately without establishing a local office.
After Legal Representation, Most Clients Move To
Common Questions
Ready to Establish Your Peru Presence?
Taevas Global's legal representation service gives pharmaceuticals manufacturers a fully compliant, DIGEMID-recognized presence in Peru from day one, so you can focus on your commercial strategy while we manage every regulatory obligation on your behalf.